Douglas Kerr Sells 1,564 Shares of Dyne Therapeutics (NASDAQ:DYN) Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) insider Douglas Kerr sold 1,564 shares of the stock in a transaction dated Wednesday, May 13th. The stock was sold at an average price of $18.36, for a total transaction of $28,715.04. Following the sale, the insider owned 170,042 shares of the company’s stock, valued at $3,121,971.12. This trade represents a 0.91% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Dyne Therapeutics Trading Down 5.4%

NASDAQ DYN opened at $17.29 on Friday. The stock has a market capitalization of $2.86 billion, a P/E ratio of -5.37 and a beta of 1.08. Dyne Therapeutics, Inc. has a 52-week low of $8.06 and a 52-week high of $25.00. The firm has a 50-day moving average price of $18.34 and a 200 day moving average price of $18.63. The company has a quick ratio of 22.25, a current ratio of 19.92 and a debt-to-equity ratio of 0.17.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.77) by $0.04. During the same quarter in the previous year, the firm earned ($1.05) EPS. Equities research analysts expect that Dyne Therapeutics, Inc. will post -2.99 EPS for the current year.

Institutional Investors Weigh In On Dyne Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. T. Rowe Price Investment Management Inc. lifted its position in shares of Dyne Therapeutics by 523.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company’s stock valued at $343,085,000 after acquiring an additional 14,727,667 shares during the period. Vanguard Group Inc. lifted its position in shares of Dyne Therapeutics by 14.9% during the 4th quarter. Vanguard Group Inc. now owns 11,215,565 shares of the company’s stock valued at $219,376,000 after acquiring an additional 1,455,151 shares during the period. State Street Corp lifted its position in shares of Dyne Therapeutics by 27.0% during the 4th quarter. State Street Corp now owns 6,692,745 shares of the company’s stock valued at $130,910,000 after acquiring an additional 1,423,828 shares during the period. Adage Capital Partners GP L.L.C. lifted its position in shares of Dyne Therapeutics by 45.5% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 5,172,000 shares of the company’s stock valued at $101,164,000 after acquiring an additional 1,618,000 shares during the period. Finally, Orbis Allan Gray Ltd acquired a new stake in shares of Dyne Therapeutics during the 4th quarter valued at approximately $93,926,000. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Dyne Therapeutics News Summary

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating and $50 price target on Dyne Therapeutics while raising several earnings estimates, suggesting analysts remain confident in the company’s longer-term prospects.
• Positive Sentiment: Lifesci Capital also lifted its earnings forecasts for Dyne Therapeutics across multiple periods, pointing to improved expectations for future results.
• Neutral Sentiment: Dyne Therapeutics’ average brokerage rating remains Moderate Buy, indicating Wall Street sentiment is still constructive overall. Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Average Rating of “Moderate Buy” by Brokerages
• Neutral Sentiment: The company recently reported a quarterly loss that was slightly better than expected, which is supportive but not a major catalyst on its own.
• Negative Sentiment: CEO John Cox, CFO Erick Lucera, and insider Douglas Kerr each sold shares this week. The filings say the sales were tied to tax withholding on equity vesting, but insider selling can still weigh on investor sentiment.

Analyst Upgrades and Downgrades

DYN has been the subject of several analyst reports. Morgan Stanley cut their price target on shares of Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating for the company in a report on Monday, March 2nd. Wall Street Zen raised shares of Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday. Weiss Ratings reissued a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Monday, April 20th. Jefferies Financial Group reissued a “buy” rating on shares of Dyne Therapeutics in a report on Monday, March 9th. Finally, Sanford C. Bernstein increased their price target on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the stock a “market perform” rating in a report on Wednesday. Three research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Dyne Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $35.00.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.